Zyvox Indications/Uses

ZYVOX formulations are indicated in the treatment of the following infections caused by susceptible strains of the designated microorganisms (see Use in Children under PRECAUTIONS and DOSAGE & ADMINISTRATION).
Linezolid is active against Gram-positive bacteria only. Linezolid has no clinical activity against Gram-negative pathogens. Specific Gram-negative therapy is required if a concomitant Gram negative pathogen is documented or suspected.
Vancomycin-Resistant Enterococcus faecium infections, including cases with concurrent bacteremia (see PHARMACOLOGY: Pharmacodynamics: CLINICAL STUDIES under Actions).
Nosocomial pneumonia caused by Staphylococcus aureus (methicillin-susceptible and -resistant strains), or Streptococcus pneumoniae [including multi-drug resistant strains (MDRSP)]. Combination therapy may be clinically indicated if the documented or presumptive pathogens include Gram-negative organisms (see PHARMACOLOGY: Pharmacodynamics: CLINICAL STUDIES under Actions).
Complicated skin and skin structure infections, including diabetic foot infections, without concomitant osteomyelitis, caused by Staphylococcus aureus (methicillin-susceptible and -resistant strains), Streptococcus pyogenes, or Streptococcus agalactiae. ZYVOX has not been studied in the treatment of decubitus ulcers. Combination therapy may be clinically indicated if the documented or presumptive pathogens include Gram-negative organisms (see PHARMACOLOGY: Pharmacodynamics: CLINICAL STUDIES under Actions).
Uncomplicated skin and skin structure infections caused by Staphylococcus aureus (methicillin-susceptible only) or Streptococcus pyogenes.
Community-acquired pneumonia caused by Streptococcus pneumoniae [including multi-drug resistant strains (MDRSP)], including cases with concurrent bacteremia, or Staphylococcus aureus (methicillin-susceptible strains only).
To reduce the development of drug-resistant bacteria and maintain the effectiveness of ZYVOX and other antibacterial drugs, ZYVOX should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy.